1st International Tremor Congress
May 11 & 12, 2018

Program Description & Objectives

Tremor is the most common movement disorders and could be highly disabling. Despite recent advancements in the diagnosis and management, patients with tremor continue to live with tremor-related disability. Current technology has created an opportunity for new diagnostic approaches, surgical procedures, and pharmacologic innovations, which holds promise for treatment of tremor. In addition, the understanding of abnormalities of brain circuitry for tremor will guide us for the development of targeted therapy. Taken together, these advances in the clinical diagnosis and patient management and also the basic science of brain circuitry of tremor will synergistically bring us to the forefront of therapy development for tremor.

In addition, there are several tremor disorders. Essential tremor (ET) is characterized by kinetic tremor whereas Parkinson’s disease (PD) tremor is classically tremor at rest. Dystonia tremor (DT) is less rhythmic and is usually associated with sustained muscle twisting movements. Tardive tremor is associated with anti-psychotic use and is part of the tardive syndrome. Therefore, the accurate diagnosis of tremor disorder also poses challenges to neurologists and movement disorders specialists. Neurologists must stay up-to-date on advances in all aspects of patient care, but, unfortunately, many rely on what they learned in medical school or residency.

Given these important challenges in the field, a need to bring together movement disorders specialists who diagnose and manage tremor patients and also basic scientists who study the abnormal brain circuits of tremor is critically important to advance the field. In other words, there is a knowledge gap among movement disorders clinicians in the understanding the brain circuitry of tremor and among basic scientists in the current diagnosis and management of clinical tremor disorders. Furthermore, recent surgical therapies and neuromodulations are developed for tremor disorders but is not well-known among the clinicians and scientists. In addition, there is a need to educate the next-generation clinicians and scientists in the knowledge of tremor.

To address these gaps, the Movement Disorders Division within the Department of Neurology of the College of Physicians & Surgeons of Columbia University will be conducting 1st International Tremor Congress, a comprehensive meeting on advances in the diagnosis and management of tremor and also the science of tremor disorders. The meeting addresses an important need for a comprehensive, academic educational program providing the latest information on innovations, insights on the latest science, and translation of the science to patient care. The conference is also consistent with the national call of the Precision Medicine Initiative for health care providers to pursue new approaches that tailor treatment to the individual patient’s characteristics. Patient response to conventional treatments for tremor is often variable; therefore, education on new surgical and medical advancements that account for individual differences can optimize outcomes for patients with tremor.

At the conclusion of this activity, participants will be better able to:

- Formulate an evidence-based approach to optimize the treatment for tremor disorders.
- Develop evidence-based scientific knowledge for the future clinical study design in tremor disorders.
- Describe the up-to-date clinical diagnosis and treatment in each tremor disorder.
- Indicate the cutting-edge scientific discovery for tremor and also current tremor therapy development.
Course Directors

Sheng-Han Kuo, M.D., Assistant Professor of Neurology, Columbia University, New York, New York

Elan D. Louis, M.D., M.S., Professor of Neurology and of Epidemiology; Chief, Division of Movement Disorders; Yale University, New Haven, Connecticut

Ming-Kai Pan, M.D., Ph.D., Assistant Professor of Medical Research, National Taiwan University, Taipei, Taiwan

Faculty

Hayriye Cagnan, Ph.D., Medical Research Council Fellow, Wellcome Trust Centre for Neuroimaging, University College London; Associate Member, University of Oxford, London, United Kingdom

Daofen Chen, Ph.D., Program Director, Systems and Cognitive Neuroscience, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

Lorraine Clark, Ph.D., Associate Professor, Department of Pathology and Cell Biology, Columbia University, New York, New York

Rodger J. Elble, M.D., Ph.D., Professor, Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois

Stanley Fahn, M.D., H. Houston Merritt Professor of Neurology; Director Emeritus, Center for Parkinson Disease and Other Movement Disorders, Department of Neurology, Columbia University, New York, New York

Phyllis Faust, M.D., Ph.D., Associate Professor, Department of Pathology and Cell Biology, Columbia University, New York, New York

Mark Hallett, M.D., Senior Investigator, Human Motor Control Section, National Institute of Neurological Disorders and Stroke; President, International Federation of Clinical Neurophysiology, Bethesda, Maryland

Rick C.G. Helmich, M.D., Ph.D., Department of Neurology, Radboud University Nijmegen Medical Center, The Netherlands

Joseph Jankovic, M.D., Professor of Neurology and Distinguished Chair of Movement Disorders; Director, Parkinson’s Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas

Un Jung Kang, M.D., H. Houston Merritt Professor of Neurology; Chief, Division of Movement Disorders, Columbia University, New York, New York

Codorin Lungu, M.D., Program Director, Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland

Mario Manto, M.D., Ph.D., FNRS-Laboratoire de Neurologie Expérimentale, Hôpital Erasme, Université Libre de Bruxelles, Belgium

William G. Ondo, M.D., Professor of Neurology; Director of Movement Disorder Clinic, Houston Methodist, Houston, Texas

Stefan Pulst, M.D., Professor and Chair of Neurology, The University of Utah, Salt Lake City, Utah

David E. Vallancourt, Ph.D., Professor, Department of Applied Physiology and Kinesiology, The University of Florida, Gainesville, Florida

Nora Vanegas - Arroyave, M.D., Assistant Professor of Neurology, Columbia University, New York, New York

Tao Xie, M.D., Ph.D., Associate Professor; Director, Parkinson & Movement Disorders Clinic; Director, DBS Program, The University of Chicago Medicine, Chicago, Illinois
Disclosure

Before the program, all faculty will disclose the existence of any financial interest and/or other relationship(s) (e.g. employee, consultant, speaker’s bureau, grant recipient, research support, stock ownership or any other special relationship) they might have with a) the manufacturer(s) of any commercial product(s) to be discussed during their presentation and/or b) any commercial contributor to this activity. When unlabeled uses are discussed, these will also be indicated.

Hayriye Cagman Ph.D.
None

Daofen Chen Ph.D.
None

Lorraine Clark Ph.D.
None

Rodger J. Elble M.D., Ph.D.
Consulting Fees
Cavion, Merz, Inc. & Biohaven Pharmaceuticals
Contracted Research
Cavion & INSIGHTEC

Stanley Fahn M.D.
Royalty
Elsevier
Commercial Consulting and Advisory Board
Membership
with honoraria
Adamas Pharmaceuticals, Retrophin Inc., PhotoPharmics, Sun Pharma Advanced Research Co, Ltd & Kashiv Pharma
Grants/Research Support
Smart Family Foundation
Lecture Honoraria
UC San Diego, Movement Disorder Society, Univ of Cincinnati, Colombian Association of Neurology, Univ of Utah, Houston Methodist Hospital, Parkinson Voice Project in Dallas
Editor Honoraria
Springer Publishers for serving as co-editor of Current Neurology and Neurosurgery Report (annual)
Author Royalties
Elsevier Publishers for co-authorship of book Principles and Practice of Movement Disorders
Employment
Columbia University
Expert Testimony
Kirkland & Ellis

Phyllis Faust M.D., Ph.D.
None

Mark Hallett M.D.
None

Rick C.G. Helmich M.D., Ph.D.
None

Joseph Jankovic M.D.*
Royalty
Contracted Research

Un Jung Kang M.D.
None

Sheng-Han Kuo M.D.
None

Elan D. Louis M.D., M.S.
None

Codrin Lungu M.D.
None

Mario Manto M.D., Ph.D.
Royalty
Springer International Publishing AG & Elsevier

William G. Ondo M.D.*
Fees received for promotional services
Teva Pharmaceutical Industries Ltd., ACADIA Pharmaceuticals Inc., US WorldMeds, LLC, UCB, Inc.
& Neurocrine Biosciences, Inc.
Contracted Research
Biogen Inc., Lundbeck LLC, Sunovion Pharmaceuticals Inc. & Cavion

Ming-Kai Pan M.D., Ph.D.
None

Stefan Puist M.D.
Joint Patent Application and MTAs
IONIS Pharmaceuticals

David E. Valliantcourt Ph.D.
Consulting Fees
Neuroimaging Solutions, Inc. (co-founder)
Contracted Research
National Institutes of Health

Nora Vanegas-Arroyave M.D.
None

Tao Xie M.D., Ph.D.*
Consulting Fees
CVS/caremark & AbbVie Inc.
Contracted Research
Michael J. Fox Foundation for Parkinson's Research,
Parkinson's Foundation, AbbVie Inc.
& Biogen, Inc.

* indicates that the speaker intends to discuss unlabeled uses of a commercial product, or an investigational use of a product not yet approved for this purpose. The speaker will disclose this information during his/her presentation.
Acknowledgments

This activity is supported by independent educational grants from:

PLATINUM
Merz North America, Inc.

GOLD
Biohaven Pharmaceuticals
Cadent Therapeutics

SILVER
Cala Health, Inc.
American Parkinson’s Disease Association
Neurocrine Biosciences, Inc.

BRONZE
Cavion Inc.
International Essential Tremor Foundation
Medtronic
Parkinson’s Foundation
INSIGHTEC

Accreditation Statements

The College of Physicians and Surgeons of Columbia University is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

The College of Physicians and Surgeons designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
May 11, 2018

8:20 a.m.  Registration; Continental Breakfast

8:55 a.m.  Welcome: 1st Tremor Congress: Focus on Circuitry
Sheng-Han Kuo, M.D.

Session 1:  Tremor Overview Moderator:
Sheng-Han Kuo, M.D.

9:00 a.m.  Tremor Research: From Phenomenology to Circuitry
Stanley Fahn, M.D.

9:30 a.m.  Overview of Brain Circuitry of Tremor
Mark Hallett, M.D.

Session 2:  Synaptic Organization of the Cerebellum in Tremor Moderator:
Elan D. Louis, M.D., M.S.

10:00 a.m.  Climbing Fiber Synaptic Organization in Tremor
Sheng-Han Kuo, M.D.

10:30 a.m.  Physiological Alterations in Tremor from Abnormal Synaptic Organization
Ming-Kai Pan, M.D., Ph.D.

11:00 a.m.  Refreshment Break

Session 3:  Axonal Re-organization of the Cerebellum in Tremor Moderator:
Un Jung Kang, M.D.

11:20 a.m.  Purkinje Cell Axonal Pathology of Essential Tumor
Phyllis Faust, M.D., Ph.D.

11:50 a.m.  Circuitry Re-organization in the Presence of Purkinje Cell Axonal Pathology
Elan D. Louis, M.D., M.S.

12:20 p.m.  Altered Physiology in Deep Cerebellar Nuclei in Tremor
Stefan Pulst, M.D.

12:50 p.m.  Group Photo

1:00 p.m.  Lunch

Session 4:  Network Alterations in Tremor Moderator:
Ming-Kai Pan, M.D., Ph.D.

2:00 p.m.  Cerebellar Circuitry and Tremor
Mario Manto, M.D., Ph.D.

2:30 p.m.  Neuroimaging for Network Re-organization in Essential Tremor
David E. Valliantcourt, Ph.D.

3:00 p.m.  Brain Network Alterations in Parkinson’s Tremor
Rick C.G. Helmich, M.D., Ph.D.

3:30 p.m.  Brain Modulations to Probe Tremor Circuitry
Hayriye Cagnan, Ph.D.

4:00 p.m.  Refreshment Break

Session 5:  Tremor Research Moderator:
Phyllis L. Faust, M.D., Ph.D.

4:30 p.m.  NINDS Program Perspectives
Daofen Chen, Ph.D. & Codrin Lungu, M.D.

4:50 p.m.  Genetics for Essential Tremor: How Do Genetic Mutations Influence the Circuitry
Lorraine Clark, Ph.D.
Poster Session Oral Abstracts (Non-CME Session)

5:20 p.m.  Deep Brain Stimulation in Early Stage Parkinson’s Disease May Prevent Rest Tremor Spread
Mallory Hacker, PhD

5:22 p.m.  Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and
Selective T-Type Calcium Modulator in Healthy Volunteers
Spyros Papapetropoulos MD, PhD

5:24 p.m.  CAD-1883, a clinical-stage positive allosteric modulator of the small conductance
calcium-activated potassium (SK) channel, slows cerebellar Purkinje neuron firing
and reduces tremor in the rat harmaline model
Gregg Keaney

5:26 p.m.  Differences in Brain Activity among Distinct Voice Tremor Phenotypes
Laura de Lima Xavier

5:28 p.m.  Longitudinal follow-up of dual-lead thalamic deep brain stimulation for patients with
treatment refractory multiple sclerosis tremor
Bhavana Patel

5:30 p.m.  MRI guided Focused Ultrasound unilateral thalamotomy for the treatment of
essential tremor: 1 year follow-up
Lydia Vela

5:32 p.m.  Non-Invasive Peripheral Nerve Stimulation for Symptomatic Relief of Hand Tremor
in Essential Tremor
Erika Ross, Ph.D.

5:34 p.m.  Examining cerebellar-thalamo-cortical network dynamics in the harmaline rodent
model of Essential Tremor
Kathryn Bennett

5:36 p.m.  Trigriluzole effectively suppresses tremor in two mouse models of tremor
Chun-Lun Ni
May 11, 2018 (Continued)

Poster Session (Non-CME Session)

1. Objective Predictors Of ‘Early Tolerance’ to Vim DBS In Essential Tremor Patients
2. Deep Brain Stimulation in Early Stage Parkinson’s Disease May Prevent Rest Tremor Spread
3. Serum Anti-Gliadin Antibodies in Cerebellar Ataxias: A Systematic Review and Meta-analysis
4. Botulinum Toxin for the Treatment of Hand Tremor
5. Proof-of-Principle Quantitative EEG Study of CX-8998, an Oral, Potent and Selective T-Type Calcium Modulator in Healthy Volunteers
6. A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Essential Tremor Patients (T-CALM): Design and Dose Selection Rationale
7. A Phase 2 Efficacy Study of an Oral, Potent and Selective T-Type Calcium (Cav3) Modulator in Parkinson’s disease Tremor (PDT) Patients: Design and Dose Selection Rationale
8. Therapeutic exposures of CX-8998, a potent, selective and state dependent Cav3 channel antagonist with dose dependent efficacy in Cav3 driven neurological models
9. CAD-1883, a clinical-stage positive allosteric modulator of the small conductance calcium-activated potassium (SK) channel, slows cerebellar Purkinje neuron firing and reduces tremor in the rat harmaline model
10. Differences in Brain Activity among Distinct Voice Tremor Phenotypes
11. Longitudinal follow-up of dual-lead thalamic deep brain stimulation for patients with treatment refractory multiple sclerosis tremor
12. Triglutizole effectively suppresses tremor in two mouse models of tremor
13. MRI guided Focused Ultrasound unilateral thalamotomy for the treatment of essential tremor: 1 year follow-up
15. Spiral Initiation: Characterization Of Distinct Manifestations of Action Tremor
16. Examining cerebellar-thalamo-cortical network dynamics in the harmaline rodent model of Essential Tremor
17. Structural and functional connectivity of the nondecussating dentato-rubro-thalamic tract
18. Ablative neurosurgery of the posterior subthalamic prelemniscal radiations in Parkinson’s disease: correlation between lesioned tracts and motor outcomes
19. Inferior olivary nucleus degeneration does not lessen tremor in essential tremor
20. Segmented versus Nonsegmented DBS Differs in Ataxic Side Effects When Implanting VIM Electrodes for Essential Tremor with Head Tremor

7:00 p.m. Adjourn

May 12, 2018

8:00 a.m. Registration; Continental Breakfast

Session 6: Novel Treatment and Device for Tremor Moderator:
Nora Vanegas-Arroyave, M.D.
9:00 a.m.  Emerging Medical and Surgical Treatments for Tremor
          William G. Ondo, M.D.

9:30 a.m.  Deep Brain Stimulation for the Treatment of Tremor: New Target and Controversy
          Tao Xie, M.D., Ph.D.

10:00 a.m. Botulinum Toxin Therapy for Tremor
          Joseph Jankovic, M.D.

10:30 a.m. Wearable Device for Tremor
          Rodger J. Elble, M.D., Ph.D.

Session 7:  Tremor Video Rounds

11:00 a.m.  Refreshment Break

11:15 a.m Video Rounds Moderators
          Sheng-Han Kuo, M.D. & Elan D. Louis, M.D., M.S.

12:45 p.m.  Closing Remarks
          Ming-Kai Pan, M.D., Ph.D.

12:50 p.m.  Adjourn